Literature DB >> 35634425

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma.

Masatoshi Kudo1.   

Abstract

Entities:  

Keywords:  Durvalumab; Hepatocellular carcinoma; Tremelimumab

Year:  2022        PMID： 35634425      PMCID： PMC9109076          DOI： 10.1159/000523702

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   12.430


× No keyword cloud information.
  14 in total

1.  Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-10-26       Impact factor: 11.740

2.  Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.

Authors:  Danbee Ha; Atsushi Tanaka; Tatsuya Kibayashi; Atsushi Tanemura; Daisuke Sugiyama; James Badger Wing; Ee Lyn Lim; Karen Wei Weng Teng; Dennis Adeegbe; Evan W Newell; Ichiro Katayama; Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-26       Impact factor: 11.205

3.  A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-03-05       Impact factor: 11.740

4.  Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.

Authors:  Rituparna Das; Rakesh Verma; Mario Sznol; Chandra Sekhar Boddupalli; Scott N Gettinger; Harriet Kluger; Margaret Callahan; Jedd D Wolchok; Ruth Halaban; Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  J Immunol       Date:  2014-12-24       Impact factor: 5.422

5.  Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.

Authors:  Thomas Yau; Joong-Won Park; Richard S Finn; Ann-Lii Cheng; Philippe Mathurin; Julien Edeline; Masatoshi Kudo; James J Harding; Philippe Merle; Olivier Rosmorduc; Lucjan Wyrwicz; Eckart Schott; Su Pin Choo; Robin Kate Kelley; Wolfgang Sieghart; Eric Assenat; Renata Zaucha; Junji Furuse; Ghassan K Abou-Alfa; Anthony B El-Khoueiry; Ignacio Melero; Damir Begic; Gong Chen; Jaclyn Neely; Tami Wisniewski; Marina Tschaika; Bruno Sangro
Journal:  Lancet Oncol       Date:  2021-12-13       Impact factor: 41.316

6.  Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

Authors:  Jeffrey S Weber; Geoff Gibney; Ryan J Sullivan; Jeffrey A Sosman; Craig L Slingluff; Donald P Lawrence; Theodore F Logan; Lynn M Schuchter; Suresh Nair; Leslie Fecher; Elizabeth I Buchbinder; Elmer Berghorn; Mary Ruisi; George Kong; Joel Jiang; Christine Horak; F Stephen Hodi
Journal:  Lancet Oncol       Date:  2016-06-04       Impact factor: 41.316

7.  Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.

Authors:  Frederick Arce Vargas; Andrew J S Furness; Kevin Litchfield; Kroopa Joshi; Rachel Rosenthal; Ehsan Ghorani; Isabelle Solomon; Marta H Lesko; Nora Ruef; Claire Roddie; Jake Y Henry; Lavinia Spain; Assma Ben Aissa; Andrew Georgiou; Yien Ning Sophia Wong; Myles Smith; Dirk Strauss; Andrew Hayes; David Nicol; Tim O'Brien; Linda Mårtensson; Anne Ljungars; Ingrid Teige; Björn Frendéus; Martin Pule; Teresa Marafioti; Martin Gore; James Larkin; Samra Turajlic; Charles Swanton; Karl S Peggs; Sergio A Quezada
Journal:  Cancer Cell       Date:  2018-03-22       Impact factor: 31.743

8.  Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.

Authors:  Richard S Finn; Masafumi Ikeda; Andrew X Zhu; Max W Sung; Ari D Baron; Masatoshi Kudo; Takuji Okusaka; Masahiro Kobayashi; Hiromitsu Kumada; Shuichi Kaneko; Marc Pracht; Konstantin Mamontov; Tim Meyer; Tomoki Kubota; Corina E Dutcus; Kenichi Saito; Abby B Siegel; Leonid Dubrovsky; Kalgi Mody; Josep M Llovet
Journal:  J Clin Oncol       Date:  2020-07-27       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.